Yuan Xu - 15 Jun 2022 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
Director
Signature
/s/ Chris Frankenfield, Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
15 Jun 2022
Transactions value $
$0
Form type
4
Filing time
17 Jun 2022, 16:30:28 UTC
Previous filing
13 Jun 2022
Next filing
07 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (right to buy) Award $0 +13.2K $0.00 13.2K 15 Jun 2022 Common Stock 13.2K $2.28 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award was granted on June 15, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 15, 2023 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service as a director of the Issuer through the vesting date.